



Money
or Down Markets

Make
In Up

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Charles Moskowitz Michael King

August 14, 2017

Market Strategies Guide to Successful Trading

**To subscribe to the Options Only Account Trades
Simply TEXT the word TRADES to the Number
and you will automatically be included.**

Market Strategies \$10,000 Options Account

Funds in Use \$ 350.00

Gain on closed Trades \$ 195.00

YTD: \$ 11,283.00

Long 8 SKYW September 40 Calls

Long 4 SPY August 243 Puts

MARKET LETTER INDEX	PG
Charles Moskowitz Discussion	1
\$10,000 Options Account	2
New Stock and Option Recommendations	2
Technical Information	3
Market Laboratory	3
Stock Positions 100,000 Acct	4
Week's Economic Numbers, Earnings Releases & Media Data	6
Fundamentals	7
Economics	9
Cycles	12
July Calendar	15
Lower Cap Stocks to Buy	16
Fundamental Stocks to Buy	20

Charles Moskowitz Discussion

Week 32 was a minor gain of \$195 bringing YTD gains to another new high of \$11,283 or 112%. We are carrying only 2 positions and funds in use are just \$680. We did well considering that we made most of the gains on the long side in a market that saw the DJIA and S&P500 make a new high and followed with a close below last week's low. The NASDAQ and Russell avoided this only because they didn't make new highs. The NASDAQ was down a whopping 3.34%, and the Russell down 2.67%. The A.A.I.I. sentiment numbers were little changed, but the bears are near long-term average and the bulls are roughly 20% under, while the neutral level is still a bit elevated.

As noted here before, geopolitical conditions are the fastest way to sway sentiment, and this week was an excellent example. As soon as the No. Korean issue worsened, the S&P500, having just run to new highs, collapsed \$20, followed by a quiet day and then on Thursday down by another \$35.

We bought a small position in the SPY puts Friday, late in the day for the Richard Donchian "weekend" rule for a follow-thru based on the weakness. There were several commentators who were discussing AMZN's dominance and how it stops innovation, since nobody wants to try to compete with the behemoth. This was followed by Jonathan Taplin, author of a new book, Mover Fast and Break Things, who brought up an alternative and opposite theory citing the 3 biggest changes that were brought on by monopoly situations; the 1956 break off of Bell Labs (AT&T) that spawned the creation of TXN, INTC, and Fairchild Camera and the chip technology, followed the IBM breakup of the company's bundling of main frame and software technology which

gave us Microsoft, and the unbundling of the Windows and the Internet Explorer, which led to Google and its group of competitors. This clearly lends to the opposite position of no innovation.

On the subject of strictly technical analysis this market shows weakness starting with the above mentioned reversal day Tuesday, and the follow-thru on Thursday after the intervening rallies that failed to make upside moves passed the prior breakdown levels. This can be seen with the 15 minute or hourly charts of any of the indexes from August 8th 9th, 10th and 11th. Until that pattern is broken it's hard to buy calls. Right now it looks like the SPY might be trying to close the gap on 7/11-7/12 between 242.55 and 243.30, as it has after every other gap in the recent past...**CAM**

All trades were based on your participation in the texting service to receive updates.

DATE		PRICE	COST	PROCEEDS	RESULTS
08/11	Bought 4 SPY August 243 Puts	1.10	440		
08/10	Sold 10 ADM August 42 Calls	0.26		260	280 Loss
08/09	Sold 10 SPY August 11 th 247 Calls	0.53		530	40 Gain
08/09	Sold 10 SPY August 11 th 247 Calls	0.14		140	130 Loss
08/09	Bought 10 SPY August 11 th 247 Calls	0.27	270		
08/09	Sold 7 SKYW Sept 40 Calls	0.90		630	420 Gain
08/08	Bought 15 SKYW Sept 40 Calls	0.30	450		
08/08	Bought 10 ADM August 42 Calls	0.54	540		
08/08	Sold 10 SPY August 11 th 248.50 Calls	0.20		200	210 Loss
08/08	Bought 10 SPY August 11 th 248 .50 Calls	0.41	480		
08/08	Sold 5 SPY August 11 th 248 Calls	1.07		535	295 Gain
08/08	Sold 5 SPY August 11 th 248 Calls (100% Profit Rule)	0.96		480	240 Gain
08/08	Bought 10 SPY August 11 th 248 Calls	0.48	480		
08/07	Sold 10 BBRY August 9.50 Calls	0.17		170	180 Loss
07/31	Bought 10 BBRY August 9.50 Calls	0.35	350		

**NEW TRADES OPTIONS ACCOUNT
NEW TRADES WILL BE TEXTED**

**NEW TRADES \$ 100 000 ACCOUNT:
NEW TRADES WILL BE TEXTED**

MARKET LABORATORY - WEEKLY CHANGES

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect

Dow 21,858.32 -234.49 -1.06%	Nasdaq 6256.56 -95.01 -1.50%	S&P 500 2441.32 +4.73 +0.19%	Transportation 9199.05 -35.51 -1.43%	Russell 2000 1374.23 -38.09 -2.70%	Nasdaq100 5831.53 -68.37 -1.16%
Gold (spot) 1287.70 +29.40 +2.2%	Silver Sept 16.252 -0.205 -1.2%	Crude July 48.82 -0.76 -1.5%	Heating Oil 1.6346 -1.22 -0.7%	Unleaded Gas 1.6130 -0.033 -2.0%	Natural Gas 2.9803 20.03 +0.206 +7.5%
VIX 15.51 +0.48 +4.8%	Put/Call Ratios S&P 100 157/100's +72/100's	Put/Call Ratios CBOE Equity 81/100's +13/100's	Bonds 155-15 +1-12 2.897%0-05.4%	10 Yr. Note 125-30 +0-6 2.29%-0305%	Copper 2.7225 +0.310 +11.5%
CRB Inflation Index 179.61 -1.07 -0.6%	Barron's* Confidence 74.8 0.7	S&P100 1081.80 -13.62 -1.24%	5 YR Note 117-27 -0+11 1.84%-0.025%	Dollar 93.07 -0.47 -0.5%	DJ Utilities 730.45 -1.42 -0.19%
AAll Confidence Index Average	Bullish 33.7% -2.4% 38.4%	Bearish 32.3% +0.2% 30.30%	Neutral 34.0% +2.2% 30.96%	M1 Money Supply +10.36% July 31 st	M2 Money Supply +4.99% July 31 st

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect * Component Change is in the Confidence Index

SUPPORT

RESISTANCE

S&P 500	2434	2500
NASDAQ (QQQ)	140.01	144.40
Trans	9000	9430
DOW	21,350	22,180
TLT	123.20	126.80

Each Stock is allocated a theoretical \$ 5,000 share of the portfolio

	Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/(\$ 920Los)
BBRY 400	11.21	06/07			
GLYC 400	12.66	06/01			
HL 500	5.72	06/01			
GSAT 1500	2.30	05/18			
SLV 300	15.78	05/15			
AGQ 150	40.39	04/07			
NUGT 75	35.68	03/13			
RWM 100	50.60	11/21			
SPXU 200	22.88	11/14			
AMBA 100	63.75	10/13			
MOS 200	27.53	05/02			
EYES 500	5.04	04/04			
EYES 1000	6.49	12/28			
TWTR 200	28.51	10/28			
MOS 100	43.55	08/14			
HL 500	3.95	05/03			
SAN 600	8.40	12/16			
TEXQY 200	6.56	7/11			
REPR* 5000	0.22	10/22/12			

Recommendations will be both listed in this letter and texted to members. Previous closed out trades can be seen on each preceding weekly market letter. X means stop loss

July 24th; 17th; 10th; 3rd; June 26th; 19th; 12th; 5th; May 9th; 22nd; 15th; 8th; 1st; April 24th; 17th; 10th; 3rd; March 7th; 20th; 13th; 6th

SCO means stop close only
Additional New Options Trades: will be texted

Large Account: Additional trades and stop losses will be Texted and E-Mailed
The new number has been provided. Call Dave Rodgers if there are problems at (832) 236- 3640.
Or Mike King 702 650 3000; Charles Moskowitz 617 827 1296

There were nine closed out options positions last week gaining \$ 560.00 in options trading. There were no closing stock trades: There are two remaining long option positions, the 15 SKYW September \$40 Calls bought at \$ 0.30 costing \$450.00 and 8 SPY August 243 Puts bought at \$1.10. The net gain for the week was \$ 650.00. The total margin requirement for options is \$1,330.00. The options expire on the third Friday of each Month unless otherwise posted. The Stock table has the following 19 positions: AGQ, BBRY, EYES (2), GLYC, GSAT, HL (2), MOS (2), NUGT, REPR, RWM, SAN, SCO, SLV, SPXU, TEXQY, TWTR,

:
The options call for a \$2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically. Money management is based on a hypothetical \$100,000.00. The 19 stock positions would cost \$79,338.00. The open long options position; the BBRY August \$9.50 Calls require \$ 1330.00; when combined with the stock requirement of \$79,338.00 equals \$80,668.00 which leaves excess cash of \$19,332.00.

YEAR TO DATE the \$100,000 Account has had 148 closed out trades between stocks, options and covered writes versus stock positions. There were no closed positions last week. There was a small decrease in equity of the open positions to a minus \$22,020.00 of the former closed positions, 101 were gains and 47 were losses. Gains to date equal \$53,215.00; losses equal \$18,689.00, for a net gain of \$34,526.00. This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Previous Week's Recommendations and Rules for the \$100,000 Account

- **Text UPDATES to number provided**
- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated.
- When the option has doubled sell half the position.
- Stop Loss protection is half if Option trades above 50 Cents or offered with each trade.
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
- Subscribers can follow us on Twitter or call 702 650 3000 for up to date information.

Note: Closed out stock and option positions can be found in previous weekly market letters: Such as

Aug 7th; July 31st; July 24th; 17th; 10th; 3rd; June 26th; 19th; 12th; 5th; May 29th; 22nd; 15th; 8th; 1st; April 24th; 17th; 10th; 3rd

Option	COST	Date	Sold	Date	Profit/(Loss)
SPY Aug 243 8 lots	<u>Puts</u> <u>1.10</u>	0911/17			
SPY Aug4th 247 20 lots	<u>Calls</u> <u>0.49</u>	08/11/17	0.53	08/09/2017	\$ 80
SPY Aug 11 th 247	<u>Calls</u> <u>0.27</u>	08/09/17	0.14	08/09/2017	(\$ 260)
SKYW Sept 40 15 lots remain	<u>Calls</u> <u>0.30</u>	08/08/17	0.90	08/09/2017	\$ 900
SPY Aug 11th 247 20 lots	<u>Calls</u> <u>0.41</u>	08/11/17	0.20	08/03/2017	(\$ 420)
ADM Aug 42	<u>Calls</u> <u>0.54</u>	08/08/17	0.26	08/10/2017	(\$ 560)
SPY Aug11 th 248 20 lots	<u>Calls</u> <u>0.48</u>	08/08/17	0.96 sold 10 (100% Profit Rule) 1.07 Sold Balance a few minutes later	08/08/2017 08/08/2017	\$ 480 \$ 590
BBRY Aug 9.50 20 lots	<u>Calls</u> <u>0.35</u>	07/31/17			

This week's Economic Numbers and Earnings Releases: Before the Open on top of the Row; After the Close below the Economics information and News releases: Space is limited:

MONDAY	<p>Canadian Solar CSIQ (-0.25 vs 0.68) JD.com JD (0.58 vs 0.29) Sysco SYU (0.72 v 0.64)</p> <p>President Donald Trump plans "internal meetings" all day Monday and Tuesday at the TrumpTower in New York, before heading back to Bedminster, N.J. on Wednesday.</p> <p>Vice President Mike Pence visits Colombia as part of his scheduled trip through Central and South America, which will take him to Argentina, Chile and Panama.</p> <p>The EnerCom Oil and Gas Conference continues in Denver.</p> <p>Atento ATTO 0.16 vs 0.13 Cancer Genetics CGIX (-0.15 vs -0.28) Extreme Networks EXTR (0.15 vs 0.10) HollySys HOLI 0.52 Photonics PLAB (0.09 vs 0.12)</p>
TUESDAY	<p>Advance Auto AAP (1.66 vs 1.90) Coach COH (0.49 vs 0.45) Dick's Sporting Goods DKS (1.01 vs 0.82) Home Depot HD (2.21 vs 1.97) TJX (0.84 vs 0.84)</p> <p>08:30 hrs Retail Sales July (0.3% vs -0.2%)</p> <p>08:30 hrs Retail Sales-ex-auto July (NA vs 0.1%)</p> <p>08:30 hrs Import Prices- ex-oil July (NA vs 0.1%)</p> <p>08:30 hrs Export Prices-ex-ag July (NA vs 0.0%)</p> <p>08:30 hrs Empire Manufacturing Aug (13 vs 9.8)</p> <p>10:00 hrs Business Inventories June (0.4% vs 0.3%)</p> <p>10:00 hrs NAHB Housing Market Index Aug (65 vs 64)</p> <p>16:00 hrs Net Long Term TIC Flows Aug (NA vs \$ 91.9B)</p> <p>Agilent A (0.52 vs 0.49) Jack Henry JKHY (0.83 vs 0.84) Phoenix New Media Limited FENG (-0.03 vs 0.01) Urban Outfitters URBN 0.37 vs 0.66 Viavi VIAV (0.08 vs 0.10)</p>
WEDNESDAY	<p>American Eagle AEO (0.16 vs 0.23) Citi Trends CTRN (0.08 vs -0.01) Performance Food Group PFGC (0.50 vs 0.38) Target TGT (1.20 vs 1.23)</p> <p>07:00 hrs MBA Mortgage Applications Index 08/12 (NA vs 3.0%)</p> <p>08:30 hrs Housing Starts July (1217K vs 1215K)</p> <p>08:30 hrs Building Permits July (1247K vs 1245K)</p> <p>10:30 hrs Crude Inventories 08/12 (NA vs -6.5Mln Bbls)</p> <p>14:00 hrs FOMC Minutes July (NA)</p> <p>Briggs & Stratton BGG (0.52 vs 0.46) Cisco Systems CSCO (0.61 vs 0.63) Ctrip CTRP (0.19 vs 0.02) L Brands LB (0.44 vs 0.70) NetApp NTAP 0.55 vs 0.46 Stein Mart SMRT (-0.17 vs 0.06) SpartanNash SPTN (0.59 vs 0.58) Vipshops VIPS (1.33 vs 0.17)</p>
THURSDAY	<p>Alibaba BABA (0.93 vs 0.74) Bitauto Holdings BITA (0.24 vs 0.20) Cato (0.11 vs 0.57) China Lodging HTHT (3.66 vs 4.67) Wal-Mart WMT (1.07 vs 1.07)</p> <p>08:30 hrs Initial Claims 08/12 (240K vs 244K)</p> <p>08:30 hrs Continuing Claims 08/12 (NA vs 1951K)</p> <p>08:30 hrs Philadelphia Fed Aug (17 vs 19.5)</p> <p>09:15 hrs Industrial Production July (0.3% vs 0.4%)</p> <p>09:15 hrs Capacity Utilization July (76.7% vs 76.6%)</p> <p>10:00 hrs Leading Indicators July (0.3% vs 0.6%)</p> <p>10:30 hrs Natural Gas Inventories 08/12(NA vs 28 bcp)</p> <p>Altaba AABA (0.15 vs 0.09) Applied Materials AMAT (0.84 vs 0.50) Baozun BZUN (0.68 vs 0.15) Gap GPS (0.53 vs 0.60) Ross Stores ROST (0.77 vs 0.71) ZOES (0.02 vs 0.06)</p>
FRIDAY	<p>Deere DE (1.90 vs 1.55) Estee Lauder EL (0.43 vs 0.43) Foot Locker FL (0.91 vs 0.94) Hibbett Sporting HIBB (-0.20 vs 0.29)</p> <p>10:00 hrs Michigan Sentiment - Prelim Aug (94.0 vs 93.4)</p> <p>The U.S. Oil Rig Count decreased by 1 Rig to 765. The Nat Gas Rig count decreased by 3 to a total of 189, making a total rig count 954. Crude closed lower at \$49.00 off \$ 0.13 or -2.6%. Natural Gas closed the week falling \$0.026 or -0.9% at \$ 2.94.</p>

FUNDAMENTALS

This weekend's disgraceful showdown in Charlottesville, Virginia drew the weakest and most tepid response from the president. It is hard not to find fault with his denunciation of "these groups" without calling them what they were. For him to not callout those that he knew participated and caused 3 deaths and untold injuries shows a lack of understanding of what his job entails and his responsibility to respond to this type of hate crime. We only mention this under the guise of the weakness of leadership is cause for concern to participants the world wide to our markets. It looks like a government in disarray and that can't help confidence for anyone.

The Dow Jones Industrials (22,092.81+262.50or +1.2%) led all indexes again for the week, duplicating its performance of the previous week making it+2.4% for the past two weeks. The Dow has strung together nine consecutive up days gaining 579.64 points making new all-time highs. Leading the way, Apple (AAPL: \$ 156.39) + \$6.89 or +4.6% and 3M Company (MMM: \$ 207.65) + \$7.93 or+ 4.0% Other out-performers included United Health Group (UNH: \$ 194.88) + \$ 3.73 or + 2%; Pfizer (PFE: \$ 33.64) +\$ 0.49 or +1.5% and Johnson and Johnson (JNJ: \$ 133.18) + \$1.33 or +1%.

The S&P 500 (2476.83) + \$4.73 or + 0.19% was the other index closing with gains for the week, even though after reaching 2480, being overbought and unable to accelerate, it just hovered sideways.

The Nasdaq Composite (6351.56) - \$ 23.11 or - 0.36% had a small loss of less than a percent for the first week in August after gaining 3.4% in July. 6250 is major support, while it can't seem to claim the 13 day moving average at 6390.The QQQ has support at 140.80.Over 144 it looks good.

The Dow Jones Transportation Average (9199.05) - \$78.58 or -0.85% was the second worst performing index last week. The 200 day price moving average has slowly risen to 9000.

Index	Started Week	Ended Week	Change	% Change	YTD %
DJIA	22092.81	21858.32	-234.49	-1.1%	10.6
Nasdaq	6351.56	6256.56	-95.00	-1.5%	16.2
S&P 500	2476.83	2441.32	-35.51	-1.4%	10.6
Russell 2000	1429.26	1412.32	-16.94	-1.2%	9.0
DJT	9277.63	9199.05	-78.58	-0.8%	1.7

US Dollar (DXYO: 93.08) -0.41 or -0.4%. The dollar continues lower with 200-week moving average support at 90.00.

Volatility (VIX: \$15.51 +\$ 5.48 or +54.6%) Volatility surged mostly on geopolitical events and secondly on expectations of a difficult 2 months ahead from seasonal domestic economic events.

CBOE OEX Volatility Index (VXO-X 12.87) + \$ 3.97 or +44.6% after making a new all-time low at 6.32, on July 25th, the index reversed sharply closing above the 200 day moving average signaling trouble ahead.

The UVXY, (\$ 43.09) or + \$ 13.30 (4 for 1 reverse equivalent)for the old shares, surged above previous major resistance at \$ 33-34, and well above the 50 day price moving average, which signals trouble for stocks going forward.

The U.S. Oil Fund (USO: \$9.99) -0.14 or -1.4%, trying to hold in a congestion area (9.95 to 10.30) from an oversold market. Oil exploration in the U.S. has been up 100.8% and gas exploration is up 133% from a year ago. Spot oil prices are up 21.2% from last year while natural gas prices are up 2.5%.

Semiconductors (SMH: \$ 85.17) -0.52 or -0.6% : Broke below the significant 50 day moving average and an important level that must hold which is a threat to a continuation of the bull market.. The action looks topy.

Gold (GLD: \$122.79 +\$ 3.14 or +2.6% Found support at the \$114.80 level and then rallied impressively to close above all moving average and the highest level since June 7th.

Russell 2000 (IWM: \$ 140.21) Closed below the critical 140 level and now poised to test the 200 day moving average at 133.50.

The GDX, the VanEck Gold Miners ETF (GDX: 22.32) - \$ 0.83or -3.6% surged above the critical 200 day moving average seeking higher levels.

Alibaba Group Holding Limited (NYSE:[BABA](#): \$151.70) -1.63 or -0.8% possibly making a double top at the \$160 level, after having rallied all year since December 30th. BABA is a market retailing leader. It rebounded nicely from oversold conditions remaining solidly bullish. Our original buy recommendation on April 11th was \$111.00/share. We would sell and take profits.

Amazon (AMZN: \$ 967.99) -19.59 or -2.0%: Climaxed at \$1083.31 and since dropped 19.59 points last week in addition to 96 points the previous week totaling a two week demise of 115 points.

Crude OIL (\$48.82) -0.76 or -1.5% Rebounded from oversold conditions with \$ 50 resistance. Energy stocks were oversold, but remain in a **bear market** supported by the overall sound economy. Look at weakness in both PBF: \$ 23.40 breaking temporarily above its 200 day moving average. Also NFX at \$26-27:

CINR has been lagging the market in 2017 since falling from around \$31.00 after its Q1 '17 earnings report. It was only slightly above its 52-week low at 8/08/17 mid-day at \$ 22.61. We would look for a new pattern to emerge at the 2016 lows around the \$ 19-20 level. The all-time high was \$ 39.10 on July 13, 2016.

Ticker	PRICE PER SHARE (8/11/17)	Performance Month	Performance Quarter	Performance Year-to-Date	Performance 1 Year	52-Week High	52-Week Low
CINR	\$24.27	-11.42%	-16.02%	-16.31%	-14.42%	-25.32%	1.89%
S&P 500	\$2,444.30	0.69%	1.86%	12.36%	9.18%	-1.87%	17.30%
Basic Materials ETF (IYM)	\$89.89	-0.71%	2.05%	8.09%	12.35%	-3.98%	19.46%

CINER (CINR: \$ 23.91) - \$2.13 or - 8.2% was a huge loser the past year and continuing down the last six months, especially the last week. Ciner Resources is part of the Ciner Enterprises Group - it owns and manages Ciner Wyoming LLC - one of the world's largest and lowest-cost producers of natural soda ash, a commodity that is used in many types of glass, soaps, detergents, paper and pulp, in addition to other categories. This stock is a takeover candidate but is not a buy yet at the current time requiring more work and a better pattern to be able to buy the stock. It is a buy-out candidate.

ECONOMICS


June Retail Sales is the first major report this week on **Tuesday** with Briefing.com expecting a gain of 0.2% vs a consensus of +0.1%, on the back of an upwardly revised 0.1% decline from -0.3% for May while sales, excluding autos, fell 0.2%. **Core Retail Sales**, which exclude auto, gasoline station, building materials, and food services and drinking places sales, declined 0.1%.

A 1.3% drop in gasoline station sales was the main drag on total retail sales along with a 0.6% decline in sales at food services and drinking places and a 0.4% decline in sales at food and beverage stores.

Building material, garden equipment and supplies dealers (+0.5%), general merchandise stores (+0.4%), and non-store retailers (+0.4%) were among the pockets of retail sales strength in June.

Core Retail Sales is the component that factors into the PCE goods component of the GDP report, so the key takeaway from the retail sales data is that it points to weak spending on consumer goods in June and will be a negative input for Q2 GDP models.

Category	JUN	MAY	APR	MAR	FEB
Retail Sales	-0.2%	-0.1%	0.3%	0.1%	-0.2%
Excluding Autos	-0.2%	-0.3%	0.3%	0.3%	0.1%
Durable goods					
Building Materials	0.5%	-0.6%	-0.1%	-1.8%	2.7%
Autos/parts	0.1%	0.9%	0.5%	-0.5%	-1.5%
Furniture	0.1%	0.1%	-0.5%	1.7%	0.4%
Nondurable goods					
General Merchandise	0.4%	-0.4%	0.9%	0.1%	-0.7%
Food	-0.4%	0.1%	0.2%	0.6%	0.0%
Gasoline stations	-1.3%	-3.0%	-0.5%	-1.0%	0.0%
Clothing	-0.1%	-0.2%	0.2%	2.0%	-2.6%
e*retailing/non-store	0.4%	0.8%	0.6%	1.2%	0.8%



Source: Census Bureau; updated 07/14/17

Briefing.com


The Consumer Price Index (CPI) report for July reported last week, showed that the “all items” index increased 0.1%. The all items index (less food and energy core CPI) also increased 0.1%. The consensus expected + 0.2%. July was the fourth month core CPI increased 0.1%. Increases in the indexes for shelter, medical care, recreation, apparel, motor vehicle insurance, and airline fares offset the declines in the indexes for new vehicles, communication, used cars and trucks, and household furnishings.

The 0.5% decrease in the index for new vehicles was the largest decline since August 2009. The 0.5% decline in the index for used cars and trucks marked the seventh consecutive decline for that index.

Those monthly readings were well below expectations and left the all items index up 1.7% year-over-year, versus 1.6% in June, and the all items index less food and energy up 1.7%, unchanged from June.

The energy index declined 0.1% in July and weighed on the all items index. A 0.2% increase in the food index helped act as an offset. The Fed will have a difficult time adjusting rates higher in light of the low inflation rate -year in July, today's CPI report isn't going to change the prevailing belief that the Fed will need to take more time to determine if inflation is picking up toward its 2.0% target on a sustained basis.

Category	JUL	JUN	MAY	APR	MAR
All Items	0.1%	0.0%	-0.1%	0.2%	-0.3%
Food and Beverages	0.2%	0.0%	0.1%	0.2%	0.3%
Housing	0.1%	0.1%	0.2%	0.3%	0.1%
Equivalent Rent	0.3%	0.3%	0.2%	0.2%	0.2%
Apparel	0.3%	-0.1%	-0.8%	-0.3%	-0.7%
Transportation	-0.1%	-0.7%	-1.4%	0.1%	-1.4%
Vehicles	-0.4%	-0.2%	-0.1%	-0.2%	-0.6%
Motor Fuel	0.0%	-2.8%	-6.4%	1.2%	-6.2%
Medical Care	0.4%	0.4%	0.0%	-0.2%	0.1%
Educ and Commun	-0.1%	0.0%	0.0%	-0.3%	-1.8%
Special Indices					
Core	0.1%	0.1%	0.1%	0.1%	-0.1%
Energy	-0.1%	-1.6%	-2.7%	1.1%	-3.2%
Services	0.2%	0.2%	0.2%	0.2%	-0.1%



Source: Bureau of Labor Statistics; updated 08/11/17

Briefing.com

Housing Starts jumped 8.3% to a seasonally adjusted annual rate of 1.215 million (Briefing.com consensus 1.160 million) after being revised up to 1.122 million (from 1.092 million) in May.


Building permits increased 7.4% to a seasonally adjusted annual rate of 1.254 million (Briefing.com consensus 1.196 million) from an unrevised 1.168 million in May. Single-family starts increased in all areas, with the exception of the Midwest (-3.6%). They were up 9.3% in the Northeast, up 7.2% in the South, and up 10.6% in the West. Single-family permits were up in all regions: Northeast (+11.5%); Midwest (+11.1%); South (+1.8%); and the West (+3.3%)

The strongest growth rates in June, however, were reserved for multi-unit starts (+13.3%) and multi-unit permits (+13.9%).

The total number of units under construction at the end of the period stood at 1.070 million, unchanged from the upwardly revised reading for May.

The key takeaway from the report is that there was solid growth in both single-family starts (+6.3%) and permits for single-family homes (+4.1%), both of which are important given the supply constraints in the housing market that have crimped affordability for many prospective home buyers

Category	JUN	MAY	APR	MAR	FEB
Starts	1215K	1122K	1154K	1189K	1288K
1 Unit	849K	799K	823K	824K	877K
Multi Units	366K	323K	331K	365K	411K
Permits	1254K	1168K	1228K	1260K	1219K



Source: Census Bureau; updated 07/19/17

Briefing.com

CYCLES

As the market appears to be succumbing to the negative news flow and sits on the brink of a steeper decline which began August 8th; the stock market has an increased vulnerability to any negative news during this perennially weak period of the year from August through September. The major averages are only off about 2-3% since their recent respective all-time highs, but most of that came last week. There is plenty of time for defensive measures.

There's been a lot of chatter comparing Trump's "Fire and Fury" threat to North Korea with Truman's Ultimatum to Japan on June 7, 1945 and the subsequent Potsdam Declaration defining the terms of Japan's surrender. JFK's battle of words and strategy with Khrushchev during the Cold War revolving around the Cuban Missile Crisis and the Berlin Wall have not been discussed as much recently, but are of similar ilk.

So we put together a few charts with facts and events plotted out against the S&P 500 to see what this latest standoff with North Korea could mean for stocks. The sell-off last week is both seasonal and also is timely to suggest the market is starting to take this current foreign policy conundrum more seriously.


In the case of Truman and Japan, the world had been at war for several grueling years and the market was rising steadily for three years from the 1942 low by the time Truman warned Japan in June of 1945. When JFK came in the market had bottomed just before he won the election in October 1960 and was rallying on his election.

North and South Korea are still at war and have been since the 1950s. They have been living with a cease fire and the protective DMZ ever since. Precisely how big of a threat does North Korea actually present to the U.S. and its allies is a difficult question to answer. But if this goes on it seems like it would play out more like the Cuban Missile Crisis, since we are currently not at war and the market has been on a tear under a new president who won in a tight race like JFK.






\$SPX: S&p 500 Index @ OPRA (Weekly bars)
www.TradeNavigator.com © 1999-2017



\$SPX: S&p 500 Index @ OPRA (Weekly bars)
www.TradeNavigator.com © 1999-2017




Almanac Investor ETF Portfolio

		Presented		8/2/2017		Buy	Stop	Auto	
Ticker	Exchange Traded Fund	Date	Price	Price	Return	Limit ¹	Loss ¹	Sell*	Current Advice ¹
XLP	SPDR Consumer Staples	9/20/16	52.05	55.22	6.1%		52.99	62.06	Hold
XLV	SPDR Healthcare	9/20/16	71.10	79.53	11.9%		71.87	85.17	Hold
XLB	SPDR Materials (S)	4/4/17	53.45	54.73	-2.3%		58.80		Hold
TLT	iShares 20+ Year Bond	5/17/17	123.50	124.71	1.0%		115.25		Hold
IYT	iShares DJ Transports (S)	5/17/17	159.74	165.09	-3.2%		175.71		Hold
XLF	SPDR Financial (S)	5/17/17	23.50	25.31	-7.2%		25.85		Hold
XLU	SPDR Utilities	5/17/17	51.60	53.75	4.2%		48.70	60.22	Hold
AGG	iShares Core US Aggregate Bond	5/17/17	109.50	109.64	0.1%		98.70		Hold
SLV	iShares Silver **	5/17/17	16.07	15.67	-2.5%				Hold
GLD	SPDR Gold	5/17/17	119.50	120.40	0.8%				Hold
FCG	First Trust Natural Gas (S)	6/6/17	20.34	20.43	-0.4%		24.15		Hold
COW	iPath Bloomberg Livestock Sub-TR ETN	6/8/17	25.00	24.23	-3.1%		23.35		Hold
DBA	PowerShares DB Agriculture	6/8/17	20.03	19.89	-0.7%		18.99		Hold
IBB	iShares NASDAQ Biotech	7/6/17	277.00	317.04	Not Yet	277.00	249.30	349.49	Buy Dips
IYW	iShares US Technology	7/6/17	124.50	146.01	Not Yet	124.50	112.05	153.25	Buy Dips
SDS	ProShares UltraShort S&P 500	7/13/17	—	48.50	Cancelled				Cancelled
FXF	CurrencyShares Swiss Franc	8/3/17	97.00	97.62	New	97.00	95.25		Buy Dips
XLE	SPDR Energy (S)	8/3/17	68.07	66.36	New	68.07			Short @ resistance or break below \$64.23
Open Position Average % Return					0.3%				
Average Total % Return					2.4%				
¹ STANDARD POLICY: SELL HALF ON A DOUBLE, Buy Limits good til cancel, Stop only if closed below Stop Loss, (S) = Short Trade, *** Spilt adjusted Current Advice is based upon closing prices as they appear in table. *Auto Sell price based upon historical sector returns plus 10%. ** Average purchase price.									


August Almanac: Weak Early and Late, Brief Strength Mid-Month

The first nine trading days of the month have exhibited weakness while mid-month is strongest. Note the bullish cluster from August 15-17. The end of August tends to get whacked as traders evacuate Wall Street for the summer finale. The last five days have suffered in 13 of the last 21 years with the S&P 500 up only five times on the next to last day in the past 21 years. In the last 21 years, the last five days of August have averaged losses of: Dow Jones Industrials, -1.0%; S&P 500, -0.9%; NASDAQ, -0.6% and Russell 2000, -0.02%.

On Monday of expiration (August 14th) the Dow has been up 15 of the last 22 times with four up more than 1%, while on expiration Friday (August 18th), it has been down six of the last seven years (-3.1% in 2015). Expiration week as a whole is down slightly more than half the time since 1990, but some of the losses have been steep (-2.6% in 1990, -2.3% in 1992, -4.1% in 1997, -4.0% in 2011, 2.2% in 2013 and 5.8% in 2015). The week after expiration is mildly stronger up 16 of the last 27.



Both charts are signaling seasonal bearishness for stocks. This trend is very much intact. The poor seasonal performance has occurred since 1987. The Asian currency crisis and the Long-Term Capital Management hedge fund debacle ending August 31, 1998 as the DJIA fell 6.4% that day. DJIA dropped a record 1344.22 points for the month, off 15.1%, which is the second worst monthly percentage DJIA loss since 1950. The chart below shows the current situation.



Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.46)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and the latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HlGH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HlGH-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare** GmbH, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HlGH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$ 10.98)

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 66.3% versus the Dow Jones +8.3%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science

divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court. Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company passed the \$ 500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 4.11*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences

entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“*PCT SPS*”).

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
 - *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
 - *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*

●and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NightFood, Inc. (NGTF 0. 20)* Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or “bites”

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies,

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We’ve seen it happen with low-carb, we’ve seen it happen with gluten-free.

Leo Motors (LEOM: \$ 0. 14)* is the premier company that develops electric vehicles (EV's) that can travel at higher speed along roads and freeways. After 10 years of field tests, the Company has surpassed obstacles of speed, torque and reliability over other e-vehicles. Leo motors has developed an array of electric vehicles and boats, including armored military vehicles, sports cars, utility trucks, passenger buses and electronic title water boats.

Leo Motors primary division, LGM, is producing and marketing electric boats (E- boats). LGM is the one of the few companies in the world that produces a safe high power electric boat. March 2017, LGM unveiled their proprietary new electric powerboat propulsion system at the 2017 Busan Boat Show in Korea. The new LGM powerboat electric propulsion system produces up to 660 horse power (HP) and is compatible with most power boats and yachts.

LGM’s electric inboard and outboard propulsion systems now range from 40 HP to 700 HP and also includes their Sailing Generation System that uses wind to recharge batteries while under way, eliminating conventional charging processes. LGM is communicating with potential partners in America for their conversion enterprise.

LGM will enter into the U.S. market this year providing electric conversion services. LGM will replace old internal combustion engine yachts and powerboats to the LGM electric power system.

Smart E-Vehicle Technology

LEO's proprietary electronic vehicle ecosystem has intelligent software which controls a cloud system. LEO developed the Vehicle to Everything (V2E) platform which uses smart technology to manage a cloud in the operating system (OS). The integrated OS allows connectivity with a smart device for improved driving solutions. The smart applications help reduce battery exchange recharge time, and provides roadside assistance. A GPS application uses satellite and mobile networks connected to Android systems using a Bluetooth®. The app sends updates, battery status and swap service information.

Skinvisible (SKVI: \$ 0.025)*Skinvisible Pharmaceuticals, Inc., is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

Fundamental Analysis: Stocks To Buy with Stops: Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. As indicated on the table below, balance is critical. And we have exited most long positions. Alibaba and Boeing have made a great deal of points. We are taking profits. We have no position in Alcoa AA. If long, raise stops to \$ 34 as a risk point. Flushing Financial FFIC fell below the 50 day price moving average on March 3rd, and again on August 9th and now has even breached the 200 day m.a. We have sold the Flushing Financial as indicated on the table. We have been looking for a place to buy Bristol Myers. Hecla Mining might be a speculative buy at a double bottom from July 7th at about \$ 4.82-86. We took profits on ENZ but still want to be long at lower prices. The HDGE is long now on our table. We have been patient waiting for the opportunity. It remains oversold and relevant at this time. It is a decent long or offset against portfolio positions.

	Name	Business Description	PE	P/S	MV mln	Current Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	Largest on-line book in China; more of a retailer than Amazon	50.67	13.21	275.5B	153.33	Bought @ \$ 111 on 4/7/17 opening	Take Profits now using \$ 160 as dbl top
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	967.99 stopped out	Sold on stop	No position
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	42.50 Stopped out 49.40	Bought 39.10 01/28/17	49.40x on June 29 th
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.48	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	25.95 Stopped out 28.90 05/04	19.40 10/31/16	Looking for place to buy
BMJ	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	56.23 No position	Looking for place to buy	If bought sell at 53.90x
BA	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	234.88	Long at 132 10/04/16	210x
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.01 Look for re-entry lower	No Position	A troubled long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3.5	592Mln	27.01 Sold on stop	19.10 bought 06/27/16	50 day m.a. at 27.45; sell belowj
HDGE	Bear ETF	Seems to stabilize at the \$ 8.50 level	NA	NA	176.8Mln	8.71	Reasonable long 8.54	8.44x
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	37.78	21.15 originally bought 2/8/16	\$ If long use \$ 34 stop
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	12.34	Bought at 5.13 10/7/16	<i>Sold on Opening Monday 4/3/17 Sold 8.43</i>
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	23.86	Bought at 15.42 9/30/16	23.60x stopped 3/21/17

Mike King
Princeton Research
3887 Pacific Street, Las Vegas, Nevada 89121

Or: Charles Moskowitz
CAM@MoneyInfo-LLC.com
617 827 1296

Phone: (702) 650-3000
Fax: (702) 697-8944
mike@princetonresearch.com or cam@princetonresearch.com
Visit: www.princetonresearch.com

Disclaimer* Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. . Princeton is paid \$ 2500 per month by Pressure Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors. Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

UNSUBSCRIBE

To unsubscribe from this newsletter, please reply to this email with UNSUBSCRIBE in the subject line. We will send you a confirmation upon completing your request.